Loading stock data…
Corvus Pharmaceuticals, Inc. (CRVS)
$13.93-0.46 (-3.20%)
Market ClosedLast close Sep 8
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Corvus Pharmaceuticals, Inc. in the Healthcare sector is trading at $13.93 with a market capitalization of $1.3B. Wall Street consensus targets $33.14 (7 analysts), implying a +137.9% move over the next 12 months. The stock is currently 48% below its 52-week high of $26.95, remaining 0.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +137.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.30M↓ | -$14.88M↓ | -$12.22M↓ | -$10.57M↓ | -$10.26M |
| Net Income | -$17.96M↓ | -$13.69M↓ | -$12.32M↓ | -$10.16M↓ | -$8.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.25B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-24.02%
Volume
Today's trading volume
1.03M
Recent News
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company’s oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. That kind of breadth from a single-asset biotech is either a […]
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript
Soquelitinib advances across multiple indications, with cash runway extended into 2028.
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ...
Corvus Pharmaceuticals Inc (CRVS) reports robust financials and progresses key clinical trials for soquelitinib across multiple indications.
Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Corvus Pharmaceuticals, Inc.'s Q2 2026 earnings call
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and